<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03534154</url>
  </required_header>
  <id_info>
    <org_study_id>230221</org_study_id>
    <secondary_id>MR/R004528/1</secondary_id>
    <nct_id>NCT03534154</nct_id>
  </id_info>
  <brief_title>Developing and Validating Blood and Imaging BIOmarkers of AXonal Injury Following Traumatic Brain Injury</brief_title>
  <acronym>BIO-AX-TBI</acronym>
  <official_title>Developing and Validating Blood and Imaging BIOmarkers of AXonal Injury Following Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Di Ricerche Farmacologiche Mario Negri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational longitudinal study assessing outcomes following moderate-severe traumatic brain&#xD;
      injury (TBI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traumatic brain injury (TBI) occurs when the brain is physically damaged, for example after a&#xD;
      car crash. It is common and survivors often have major on-going problems. It is very&#xD;
      difficult to predict how patients will do after TBI. One reason for this is that clinicians&#xD;
      and researchers are unable to measure all the effects of TBI. An important factor is that the&#xD;
      connections between nerve cells are damaged by the impact on the brain of an injury (axonal&#xD;
      injury). This damage has been difficult to measure in the past, but new ways to scan the&#xD;
      brain and more sensitive ways of picking up the effects of this injury in the blood could&#xD;
      change this. In other parts of medicine tests of this type have had a dramatic effect on how&#xD;
      clinicians treat patients. For example, the products of heart muscle damage that have leaked&#xD;
      into the blood can be used identify a heart attack and guide treatment. Clinicians need&#xD;
      similar tests to be available in TBI. This should be possible as the products of axonal&#xD;
      injury also leak into the blood and researchers have a sensitive way to pick this up. An&#xD;
      accurate test for axonal injury would guide treatment choices and allow clinicians to predict&#xD;
      how patients will recover. The investigators have brought together an international team who&#xD;
      have been working on different aspects of this problem for many years. Together the&#xD;
      investigators will conduct a large study to identify the best measures of axonal injury. The&#xD;
      investigators will carefully test whether these measures help predict outcomes and will study&#xD;
      where the blood markers come from using a safe method to measure the effects of axonal injury&#xD;
      directly from the brain. The work links into some large projects that have already started&#xD;
      and will use a standard way to assess patients after their injury. This is important because&#xD;
      it will allow researchers to share results across studies. The investigators hope the work&#xD;
      will allow us to identify a blood marker for TBI that could be widely used to quickly&#xD;
      identify the presence of axonal injury. The investigators will also show what brain imaging&#xD;
      measure is best at picking up axonal injury and how best to combine the measures to best&#xD;
      predict how patients recover. This will allow doctors to diagnose problems after TBI more&#xD;
      accurately, choose the right treatments and give patients and their families accurate advice&#xD;
      about what will happen after discharge from hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in diffusion tensor imaging measures over time</measure>
    <time_frame>10 days - 6 weeks, 6 months and 12 months</time_frame>
    <description>Fractional anisotropy (FA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain atrophy rates</measure>
    <time_frame>10 days - 6 weeks, 6 months and 12 months</time_frame>
    <description>Brain tissue volume changes over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of fluid biomarkers in blood</measure>
    <time_frame>0-5 days, 5-10 days, 10 days - 6 weeks, 6 months and 12 months</time_frame>
    <description>Neurofilament light and Tau protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of fluid biomarkers in cerebral fluid</measure>
    <time_frame>48 hours to 7 days</time_frame>
    <description>Neurofilament light and Tau protein</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>TBI - MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <description>Work package 1. In a large multi-centre cohort of adult moderate/severe TBI patients we aim to identify the most informative plasma biomarker(s) of the severity of axonal injury. We will characterise their time course, focusing on neurofilament light (NFL) and tau, and relate these to magnetic resonance imaging (MRI) measures of axonal injury. Using logistic regression we will then test whether these measures contribute to the prediction of clinical outcome at twelve months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBI - Advanced MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <description>Work package 2. In a subgroup of the patients recruited to WP1 we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion and myelin integrity measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBI - microdialysis / adv. MRI / cognitive / clinical</arm_group_label>
    <description>Work package 3. In a second subgroup of patients recruited to WP1 we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <description>Single assessment using MRI, bloods and cognitive testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Magnetic Resonance Imaging</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_label>TBI - Advanced MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <arm_group_label>TBI - MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <arm_group_label>TBI - microdialysis / adv. MRI / cognitive / clinical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Sampling</intervention_name>
    <description>Sampling of serum</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_label>TBI - Advanced MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <arm_group_label>TBI - MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <arm_group_label>TBI - microdialysis / adv. MRI / cognitive / clinical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Microdialysis</intervention_name>
    <description>Monitoring of cerebral fluid protein levels</description>
    <arm_group_label>TBI - microdialysis / adv. MRI / cognitive / clinical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neuropsychological tests</intervention_name>
    <description>Battery of tests to assess cognitive function, patient outcomes</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_label>TBI - Advanced MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <arm_group_label>TBI - MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <arm_group_label>TBI - microdialysis / adv. MRI / cognitive / clinical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI (advanced)</intervention_name>
    <description>Advanced MRI</description>
    <arm_group_label>TBI - Advanced MRI / bloods / cognitive / clinical outcomes</arm_group_label>
    <arm_group_label>TBI - microdialysis / adv. MRI / cognitive / clinical</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and cerebral microdialysis samples collected during longitudinal study, where&#xD;
      appropriate (as per protocol).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        250 traumatic brain injury patients from ITU / major trauma ward.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of moderate/severe traumatic brain injury (TBI) as classified using the&#xD;
             Mayo classification system;&#xD;
&#xD;
          -  Healthy controls will be age-matched to our TBI patients and will not have a history&#xD;
             of significant neurological or psychiatric conditions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures required&#xD;
&#xD;
          -  Bilateral fixed dilated pupils&#xD;
&#xD;
          -  For MRI, contra-indication to MRI scanning, assessed by a standard pre-MRI&#xD;
             questionnaire (e.g. presence of ferromagnetic implants in the body, claustrophobia,&#xD;
             pregnancy) if considered for the imaging strand of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Sharp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS, Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto di Ricerche Farmacologiche &quot;Mario Negri&quot;</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Slovenia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Graham NSN, Zimmerman KA, Bertolini G, Magnoni S, Oddo M, Zetterberg H, Moro F, Novelli D, Heslegrave A, Chieregato A, Fainardi E, Fleming JM, Garbero E, Abed-Maillard S, Gradisek P, Bernini A, Sharp DJ. Multicentre longitudinal study of fluid and neuroimaging BIOmarkers of AXonal injury after traumatic brain injury: the BIO-AX-TBI study protocol. BMJ Open. 2020 Nov 10;10(11):e042093. doi: 10.1136/bmjopen-2020-042093.</citation>
    <PMID>33172948</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

